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OBJECTIVE — To evaluate the association between 25-hydroxyvitamin D [25(OH)D] and
metabolic syndrome in the Chinese population.
RESEARCH DESIGN AND METHODS — Plasma 25(OH)D was measured in a cross-
sectional sample of 1,443 men and 1,819 women aged 50–70 years from Beijing and Shanghai.
Metabolic syndrome was deﬁned according to the updated National Cholesterol Education
ProgramAdultTreatmentPanelIIIcriteriaforAsianAmericans.Fastingplasmaglucose,insulin,
lipid proﬁle, A1C, and inﬂammatory markers were measured.
RESULTS — The geometric mean of plasma 25(OH)D was 40.4 nmol/l, and percentages of
vitamin D deﬁciency [25(OH)D 50 nmol/l] and insufﬁciency [50  25(OH)D 75 nmol/l]
were 69.2 and 24.4%, respectively. Compared with the highest 25(OH)D quintile (57.7
nmol/l), the odds ratio for metabolic syndrome in the lowest quintile (28.7 nmol/l) was 1.52
(95% CI 1.17–1.98, Ptrend  0.0002) after multiple adjustment. Signiﬁcant inverse associations
also existed between 25(OH)D and individual metabolic syndrome components plus A1C.
Moreover, we observed signiﬁcant inverse associations of 25(OH)D with fasting insulin and the
insulin resistance index (homeostasis model assessment of insulin resistance [HOMA-IR]) in
overweightandobeseindividuals(BMI24kg/m
2)butnotintheirnormal-weightcounterparts
(test for interaction: P  0.0363 and 0.0187 for insulin and HOMA-IR, respectively).
CONCLUSIONS — Vitamin D deﬁciency is common in the middle-aged and elderly Chi-
nese population, and a low 25(OH)D level is signiﬁcantly associated with an increased risk of
having metabolic syndrome and insulin resistance. Prospective studies and randomized clinical
trialsarewarrantedtodeterminetheroleof25(OH)Dinthedevelopmentofmetabolicsyndrome
and related metabolic diseases.
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V
itamin D deﬁciency is now recog-
nizedasaworldwideconcern(1).A
growing body of evidence suggests
that 25-hydroxyvitamin D [25(OH)D], a
generally accepted indicator of vitamin D
status,isinverselyassociatedwithadipos-
ity, glucose homeostasis, lipid proﬁles,
and blood pressure along with its classic
roleincalciumhomeostasisandboneme-
tabolism (1–6). Even though the under-
lying mechanism has not been well
understood, vitamin D appears to exert
effects through direct modulation of gene
expression via vitamin D receptors
(VDRs) (1) and through regulation of ex-
tra- and intracellular calcium (1,7).
Metabolic syndrome, a constellation
of cardiometabolic disease risk factors,
hasbecomeaglobalepidemic(8).Several
epidemiologic studies (5,6,9,10) have
suggested that 25(OH)D status is in-
versely associated with metabolic syn-
drome in western populations, although
data for morbidly obese individuals are
inconsistent (11,12). Nevertheless, evi-
dence from the Asian population is lim-
ited. Because of ethnic differences in
vitamin D metabolism and its nutritional
status indicated by previous studies
(3,13), it is not clear whether the ﬁndings
from western populations could be ex-
trapolated directly to Asian individuals.
With rapid nutrition and lifestyle transi-
tions in the last 20 years, metabolic syn-
drome has become one of the most
widespread health problems in Asian
countries(8).However,littleisknownre-
garding whether vitamin D deﬁciency
plays an important role in the heightened
prevalence of metabolic syndrome and
other metabolic disorders among Asian
individuals. Therefore, the aim of our
study was to evaluate the plasma
25(OH)D concentration and its associa-
tion with metabolic syndrome among
Chinese individuals aged 50–70 years.
RESEARCH DESIGN AND
METHODS— The present study is a
part of the Nutrition and Health of Aging
Population in China (NHAPC) project,
which is a population-based cross-
sectional study among noninstitutional-
ized Chinese individuals aged 50–70
years in Beijing (latitude 40° north) and
Shanghai(latitude31°north),China.The
details of the study design have been de-
scribedpreviously(14).Inbrief,thestudy
was conducted simultaneously in both
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Insti-
tutes for Biological Sciences, Chinese Academy of Sciences and Graduate School of the Chinese Academy
ofSciences,Shanghai,China;the
2DepartmentsofNutritionandEpidemiology,HarvardSchoolofPublic
Health,Boston,Massachusetts;the
3HealthSciencesResearchInstitute,UniversityofWarwick,Coventry,
U.K.; the
4Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endo-
crinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
China; and the
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong
Kong SAR, China.
Corresponding author: Xu Lin, xlin@sibs.ac.cn.
Received 4 February 2009 and accepted 4 April 2009.
Published ahead of print at http://care.diabetesjournals.org on 14 April 2009. DOI: 10.2337/dc09-0209.
L.L. and Z.Y. contributed equally to this work.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE
1278 DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009geographic locations from April to June
2005. In each city, one rural and two ur-
ban districts were selected. A total of
3,289 eligible participants (1,458 men
and 1,831 women) were recruited. After
excluding those who did not have ade-
quate blood samples for 25(OH)D mea-
surement (n  27), 3,262 individuals
were eligible for the present analysis. The
study was approved by the institutional
review board of the Institute for Nutri-
tional Sciences, and all participants pro-
vided informed consent.
Data collection
Inahomeinterview,astandardizedques-
tionnaire was used by trained health
workers to collect information such as
age, sex, geographic location (Beijing/
Shanghai), residential region (urban/
rural), visit date (April or May/June),
educationlevel(6,7–9,or10yearsin
school), smoking (current, former, or
never), alcohol drinking (yes/no), and
self-reporteddiabetes,hypertension,dys-
lipidemia, coronary heart disease (CHD),
stroke, and medication use. Physical ac-
tivity level was classiﬁed as low, moder-
ate, or high according to the International
PhysicalActivityQuestionnaire(shortlast
7-day format) scoring protocol with mi-
nor modiﬁcation (14). According to par-
ticipants’ responses to the corresponding
questions, family history of cardiovascu-
lar disease (CVD) or diabetes was classi-
ﬁed as yes or no.
After the home interview, all partici-
pants were invited to attend a physical
examination after an overnight fast. Mea-
surements of weight, height, waist cir-
cumference, and blood pressure have
been described previously (14). BMI was
calculated as weight in kilograms divided
by the square of height in meters and cat-
egorizedasnormalweight(24.0kg/m
2)
or overweight or obesity (24.0 kg/m
2),
according to the criteria for Chinese indi-
viduals (15).
Laboratory methods
Peripheral venous blood samples were
collectedintubescontainingliquidEDTA
and centrifuged at 4°C. After being fro-
zen, the samples were shipped on dry ice
to the Institute for Nutritional Sciences
andstoredat–80°Cuntilanalysis.Plasma
glucose, triglycerides, and HDL choles-
terol were measured enzymatically on an
automatic analyzer (Hitachi 7080) with
reagents purchased from Wako Pure
Chemical Industries (Osaka, Japan). A1C
wasquantiﬁedfromresolvederythrocytes
with an automated immunoassay (Tina-
quant Hemoglobin A1C II; Roche Diag-
nostics, Indianapolis, IN), which was
standardized according to the Diabetes
Control and Complications Trial/
National Glycohemoglobin Standardiza-
tion Program. Plasma high-sensitive
C-reactive protein (CRP) was measured
by a particle-enhanced immunoturbidi-
metric assay (Ultrasensitive CRP kit;
Orion Diagnostica, Espoo, Finland). In-
terleukin-6 (IL-6) was measured using a
high-sensitivity ELISA (Quantikine HS
IL-6 Immunoassay; R&D Systems, Min-
neapolis, MN). Fasting insulin was deter-
mined by radioimmunoassay (Linco
Research, St. Charles, MO). The insulin
resistance index (homeostasis model as-
sessment of insulin resistance [HOMA-
IR]) was calculated using updated
homeostasis model assessment methods
(http://www.dtu.ox.ac.uk/). The plasma
25(OH)Dconcentrationwasassayedwith
a radioimmunoassay kit (DiaSorin, Still-
water, MN). Vitamin D nutritional status
was assessed as “sufﬁciency” (75 nmol/l),
“insufﬁciency” [50  25(OH)D 75
nmol/l],or“deﬁciency”(50nmol/l)(1).
Alloftheintra-andinterassaycoefﬁcients
of variation were 13%.
Deﬁnition of the metabolic
syndrome
Metabolic syndrome was deﬁned using
the updated National Cholesterol Educa-
tion Program Adult Treatment Panel III
criteria for Asian Americans (16) as pre-
sentationofthreeormoreofthefollowing
components: 1) waist circumference 90
cm for men or 80 cm for women; 2)
triglycerides 1.7 mmol/l; 3) HDL cho-
lesterol 1.03 mmol/l for men or 1.30
mmol/l for women; 4) blood pressure
130/85mmHgorcurrentuseofantihy-
pertensive medications; and 5) fasting
glucose 5.6 mmol/l or previously diag-
nosed type 2 diabetes or using oral hypo-
glycemic agents or insulin.
Statistical methods
The difference in plasma 25(OH)D con-
centrations between participants with
and without metabolic syndrome was
tested by the general linear model with
controls for age, sex, geographic location,
residential region, and visit date. A logis-
tic regression model was used to evaluate
theoddsratios(ORs)and95%CIsofhav-
ing metabolic syndrome for each quintile
of 25(OH)D compared with the highest
quintile with adjustment for potential
confounders that were suggested in pre-
viousstudies(3,5,6,9,17).Inaddition,ef-
fects of inﬂammatory factors on the
association between 25(OH)D and meta-
bolicsyndromeweretestedbymodelsad-
justed for CRP and IL-6. Tests of linear
trend across increasing quintiles of
25(OH)D were performed by assigning
the median value to each quintile and
treatingitasacontinuousvariable.Amul-
tiple linear regression model was used to
assess the association of 25(OH)D (con-
tinuous) with fasting glucose, A1C, waist
circumference,triglycerides,HDLcholes-
terol, blood pressure, fasting insulin, and
HOMA-IR. A likelihood ratio test was
used to test the potential modifying effect
of sex and obesity status (24 or 24
kg/m
2). When appropriate, natural log-
transformed values were used for the
analyses. Statistical inference was made
with P  0.05 (two-sided). The statistical
analyses were performed using Stata 9.2
(StataCorp, College Station, TX).
RESULTS— The geometric mean of
25(OH)D was 40.4 nmol/l in our study
participants. The percentages of vitamin
D deﬁciency, insufﬁciency, and sufﬁ-
ciencywere69.2,24.4,and6.4%,respec-
tively. Across 25(OH)D quintiles,
subjectsinlower25(OH)Dquintileswere
more likely to be northern (Beijing) and
urban residents, to have a physical exam-
ination in April, to have higher educa-
tional levels, and to have a family history
of CVD and diabetes. They also tended to
have an adverse cardiometabolic proﬁle.
Inaddition,thesesubjectswerelessphys-
icallyactiveandwerelesslikelytobemale
and alcohol drinkers than those in higher
25(OH)D quintiles (Table 1).
Plasma 25(OH)D concentrations
were lower in participants with metabolic
syndrome than in those without meta-
bolicsyndrome(39.3vs.41.6nmol/l,P
0.0001). The risk of having metabolic
syndrome increased progressively across
the highest to the lowest quintiles of
25(OH)D with the ORs of 1.31 (95% CI
1.03–1.66), 1.36 (95% CI 1.07–1.73),
1.67 (95% CI 1.31–2.13), and 1.62 (95%
CI 1.26–2.08), respectively (Ptrend 
0.0001) (Table 2) after adjustment for
age, sex, geographic location, residential
region, and visit date (model 1). Further
controlsforeducation,behavioralfactors,
self-reported CHD, and stroke and family
history of CVD and diabetes (model 2)
did not materially change the inverse as-
sociations. After additional adjustment
for CRP and IL-6 (model 3), the ORs at-
tenuated slightly, but remained signiﬁ-
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appeared to be stronger in men than in
women (data not shown), although the
interactionforsexwasnotstatisticallysig-
niﬁcant (P  0.1745). When study par-
ticipants were dichotomized with the
cutoff point of 50 nmol/l, the risk of hav-
ing metabolic syndrome was 27% higher
in those with an 25(OH)D concentration
50 nmol/l (OR 1.27; 95% CI 1.06–
1.53) than in those with a concentration
50 nmol/l after controlling for all the
covariates in model 3.
In both simple and multiple adjusted
linear regression analyses, 25(OH)D was
inversely associated with fasting glucose,
A1C, triglycerides, waist circumference,
and diastolic blood pressure and posi-
tively associated with HDL cholesterol
(Table 3). Further adjustment for BMI
(notforwaistcircumference)didnotsub-
stantially alter the associations. Sex-
speciﬁc interactions were observed in the
associations of 25(OH)D with triglycer-
ides and HDL cholesterol (test for inter-
action: P  0.0034 and 0.0027 for
triglycerides and HDL cholesterol, re-
spectively), and both associations were
onlysigniﬁcantinmenbutnotinwomen.
There were negative associations of
25(OH)D with fasting insulin and
HOMA-IR in the total population (P 
0.0114 and 0.0044 for insulin and
HOMA-IR,respectively),aftercontrolling
for potential confounding factors (Table
3). We further observed a modifying ef-
fect of obesity status on these associations
(test for interaction: P  0.0363 and
0.0187forinsulinandHOMA-IR,respec-
tively). In stratiﬁed analyses, 25(OH)D
was negatively associated with fasting in-
sulin and HOMA-IR only in participants
with BMI 24 kg/m
2 (P  0.0001 and
P  0.0001 for insulin and HOMA-IR,
respectively) but not in those with BMI
24 kg/m
2 (P  0.5948 and 0.5874 for
insulin and HOMA-IR, respectively).
Table 1—Characteristics of study participants according to 25(OH)D quintiles
Quintiles of 25(OH)D
Q1: 28.7
nmol/l
Q2: 28.8–36.8
nmol/l
Q3: 36.9–45.5
nmol/l
Q4: 45.6–57.6
nmol/l
Q5: 57.7
nmol/l
n 652 653 652 653 652
Age (years) 58.8  6.3 58.1  6.0 58.8  5.9 58.2  5.9 59.1  5.9
Male sex 233 (35.7) 252 (38.6) 279 (42.8) 311 (47.6) 368 (56.4)
Urban residents 423 (64.9) 384 (58.8) 367 (56.3) 260 (39.8) 189 (29.0)
Residents of Beijing 466 (71.5) 419 (64.2) 331 (50.8) 238 (36.5) 168 (25.8)
Visit date (April) 433 (66.4) 389 (59.6) 334 (51.2) 245 (37.5) 183 (28.1)
Smoking
Never 395 (60.6) 422 (64.6) 423 (64.9) 409 (62.6) 376 (57.7)
Former 67 (10.3) 51 (7.8) 63 (9.7) 59 (9.0) 87 (13.3)
Current 190 (29.1) 180 (27.6) 166 (25.5) 185 (28.3) 189 (29.0)
Alcohol drinking, yes 167 (25.6) 183 (28.0) 189 (29.0) 193 (29.6) 196 (30.1)
Physical activity
Low 63 (9.7) 40 (6.1) 47 (7.2) 50 (7.7) 43 (6.6)
Moderate 310 (47.6) 307 (47.0) 294 (45.1) 228 (34.9) 230 (35.3)
High 279 (42.8) 306 (46.9) 311 (47.7) 375 (57.4) 379 (58.1)
Education
0–6 years 201 (30.8) 223 (34.2) 240 (36.8) 317 (48.6) 371 (56.9)
7–9 years 278 (42.6) 254 (38.9) 249 (38.2) 201 (30.8) 177 (27.2)
10 years 173 (26.5) 176 (27.0) 163 (25.0) 135 (20.7) 104 (16.0)
Hypertension* 373 (57.2) 372 (57.0) 367 (56.3) 329 (50.4) 344 (52.8)
Self-reported CHD† 67 (10.6) 54 (8.4) 48 (7.6) 29 (4.6) 28 (4.4)
Self-reported stroke‡ 33 (5.1) 32 (4.9) 23 (3.5) 24 (3.7) 19 (2.9)
Family history of diabetes 105 (16.1) 89 (13.6) 86 (13.2) 93 (14.2) 74 (11.4)
Family history of CVD 179 (27.5) 154 (23.6) 152 (23.3) 149 (22.8) 97 (14.9)
BMI (kg/m
2) 24.9  3.8 24.9  3.8 24.6  3.6 24.3  3.2 23.5  3.3
Waist circumference (cm) 85.2  10.5 84.7  10.7 84.2  10.8 83.2  10.1 81.3  10.2
Fasting glucose (mmol/l) 5.52 (5.08–6.09) 5.46 (5.09–6.00) 5.46 (5.09–5.98) 5.42 (4.99–5.88) 5.28 (4.96–5.72)
A1C (%) 5.76 (5.46–6.22) 5.75 (5.48–6.14) 5.73 (5.46–6.10) 5.78 (5.47–6.11) 5.68 (5.39–6.02)
Insulin (pmol/l)§ 87.0 (61.2–123.0) 87.0 (60.0–120.6) 82.2 (61.2–113.4) 80.7 (59.4–106.8) 73.8 (55.2–99.3)
HOMA-IR 1.67 (1.18–2.30) 1.66 (1.17–2.26) 1.59 (1.18–2.12) 1.52 (1.14–2.02) 1.40 (1.07–1.88)
Triglycerides (mmol/l) 1.15 (0.83–1.82) 1.17 (0.82–1.80) 1.15 (0.80–1.71) 1.06 (0.73–1.61) 0.92 (0.65–1.38)
HDL cholesterol (mmol/l) 1.25  0.34 1.27  0.33 1.27  0.33 1.27  0.33 1.32  0.33
CRP (mg/l) 0.79 (0.36–1.92) 0.74 (0.35–1.68) 0.67 (0.33–1.49) 0.60 (0.32–1.37) 0.59 (0.29–1.25)
IL-6 (pg/ml)¶ 1.13 (0.73–1.86) 1.07 (0.73–1.65) 1.00 (0.62–1.49) 1.06 (0.69–1.57) 0.94 (0.61–1.49)
Data are means  SD, n (%), or median (interquartile range). *Blood pressure 140/90 mmHg, or current use of anti-hypertensive medications. †77 participants
were excluded with a missing value for self-reported CHD. ‡10 participants were excluded with a missing value for self-reported stroke. §4 participants were
excluded with a missing value of fasting insulin. 23 participants were excluded with a missing value for HOMA-IR. ¶89 participants were excluded with a missing
value for IL-6.
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were divided into 25(OH)D quintiles, the
multivariate-adjusted geometric mean of
fasting insulin was 13.86 pmol/l lower
(P  0.0003) and HOMA-IR was 0.26
lower(P0.0002)fortheparticipantsin
the highest quintile compared with those
in the lowest. Excluding those with diag-
nosed diabetes and CVD yielded similar
results patterns (data not shown).
CONCLUSIONS— We observed that
94% of our study participants had
25(OH)D deﬁciency or insufﬁciency. A
lower 25(OH)D concentration was associ-
atedwithincreasedriskofhavingmetabolic
syndrome and its individual components.
In addition, poor 25(OH)D status was also
signiﬁcantlyassociatedwithincreasedinsu-
lin resistance, especially among those who
were overweight or obese.
Table 2—Adjusted ORs (95% CI) of having metabolic syndrome according to quintiles of plasma 25(OH)D concentrations
Quintiles of 25(OH)D
Ptrend
Q5: 57.7
nmol/l
Q4: 45.6–57.6
nmol/l
Q3: 36.9–45.5
nmol/l
Q2: 28.8–36.8
nmol/l
Q1: 28.7
nmol/l
No. cases/participants 193/652 248/653 279/652 326/653 335/652
Model 1 1.00 (reference) 1.31 (1.03–1.66) 1.36 (1.07–1.73) 1.67 (1.31–2.13) 1.62 (1.26–2.08) 0.0001
Model 2 1.00 (reference) 1.31 (1.02–1.66) 1.38 (1.08–1.77) 1.76 (1.37–2.26) 1.64 (1.27–2.13) 0.0001
Model 3 1.00 (reference) 1.28 (1.00–1.64) 1.33 (1.03–1.71) 1.71 (1.32–2.21) 1.52 (1.17–1.98) 0.0002
Model 1: adjusted for age, sex, geographic location (Beijing/Shanghai), residential region (urban/rural), and visit date (April or May/June). Model 2: further adjusted
for education (6, 7–9, or 10 years in school), physical activity (low, moderate, or high), smoking (current, former, or never), alcohol drinking (yes/no), family
history of CVD (yes/no) and diabetes (yes/no), and self-reported CHD (yes/no) and stroke (yes/no). Model 3: further adjusted for inﬂammatory factors (CRP and
IL-6).
Table 3—Adjusted regression coefﬁcients of 25(OH)D with components of metabolic syndrome, A1C, fasting insulin, and HOMA-IR
Model 1 Model 2 Model 3 Model 4
 (SEM) P  (SEM) P  (SEM) P  (SEM) P
All (N  3,262)
Fasting glucose (mmol/l) 0.17 (0.08) 0.0277 0.17 (0.08) 0.0337 0.18 (0.08) 0.0262 0.17 (0.08) 0.0281
A1C (%) 0.21 (0.05) 0.0001 0.20 (0.05) 0.0001 0.21 (0.05) 0.0001 0.21 (0.05) 0.0001
Fasting insulin (pmol/l)* 0.08 (0.02) 0.0004 0.07 (0.02) 0.0036 0.06 (0.02) 0.0088 0.06 (0.02) 0.0114
HOMA-IR† 0.09 (0.02) 0.0002 0.07 (0.02) 0.0014 0.07 (0.02) 0.0035 0.06 (0.02) 0.0044
Waist circumference (cm) 1.61 (0.46) 0.0005 1.64 (0.47) 0.0005 1.46 (0.48) 0.0023 — —
Triglycerides (mmol/l)‡ 0.13 (0.03) 0.0001 0.12 (0.03) 0.0001 0.11 (0.03) 0.0001 0.10 (0.03) 0.0001
HDL cholesterol (mmol/l)§ 0.07 (0.01) 0.0001 0.07 (0.02) 0.0001 0.06 (0.02) 0.0001 0.06 (0.01) 0.0001
Diastolic blood pressure
(mmHg) 1.29 (0.48) 0.0072 1.32 (0.49) 0.0074 1.25 (0.50) 0.0122 1.15 (0.48) 0.0169
Systolic blood pressure
(mmHg) 1.37 (0.95) 0.1486 1.52 (0.98) 0.1185 1.28 (0.99) 0.1964 1.08 (0.95) 0.2577
Sex
Men (n  1,443)
Triglycerides (mmol/l) 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001 0.19 (0.04) 0.0001
HDL cholesterol (mmol/l) 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001 0.10 (0.02) 0.0001
Women (n  1,819)
Triglycerides (mmol/l) 0.07 (0.04) 0.0574 0.04 (0.04) 0.2554 0.03 (0.04) 0.4546 0.02 (0.03) 0.5907
HDL cholesterol (mmol/l) 0.03 (0.02) 0.0841 0.03 (0.02) 0.1182 0.02 (0.02) 0.3121 0.02 (0.02) 0.4327
Obesity status
BMI 24 kg/m
2 (n  1,526)
Fasting insulin (pmol/l) 0.04 (0.03) 0.2653 0.03 (0.03) 0.4596 0.02 (0.04) 0.5948 — —
HOMA-IR 0.03 (0.03) 0.2977 0.02 (0.03) 0.4530 0.02 (0.03) 0.5874 — —
BMI 24 kg/m
2 (n  1,736)
Fasting insulin (pmol/l) 0.14 (0.03) 0.0001 0.13 (0.03) 0.0001 0.12 (0.03) 0.0001 — —
HOMA-IR 0.15 (0.03) 0.0001 0.13 (0.03) 0.0001 0.13 (0.03) 0.0001 — —
25(OH)D, fasting insulin, HOMA-IR, and triglycerides were log-transformed before analysis. Model 1: adjusted for age, sex (not for sex-stratiﬁed analysis),
geographiclocation(Beijing/Shanghai),residentialregion(urban/rural),andvisitdate(AprilorMay/June).Model2:furtheradjustedforeducation(6,7–9,or10
years in school), physical activity (low, moderate, or high), smoking (current, former, or never), alcohol drinking (yes/no), family history of CVD (yes/no) and
diabetes (yes/no), and self-reported CHD (yes/no) and stroke (yes/no). For fasting glucose, A1C, fasting insulin, and HOMA-IR, hypertension (yes/no) was included
inthemodel.Model3:furtheradjustedforinﬂammatoryfactors(CRPandIL-6,continuousvariables).Model4:furtheradjustedforBMI(notforwaistcircumference
and obesity status-stratiﬁed analysis). *4 participants were excluded with a missing value of fasting insulin; P for interaction between 25(OH)D and obesity status 
0.0363. †23 participants were excluded with a missing value of HOMA-IR; P for interaction between 25(OH)D and obesity status  0.0187. §P for interaction
between 25(OH)D and sex  0.0034. §P for interaction between 25(OH)D and sex  0.0027.
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the VDR gene polymorphism was not as-
sociated with metabolic syndrome
(18,19), the inverse association between
25(OH)Dandmetabolicsyndromefound
in our study is consistent with that from
three previous cross-sectional reports in
American (9,10) and British adults (6).
These three studies (6,9,10) were also
performed in the general population with
large sample sizes; two American studies
(9,10) included subjects aged 20 years
and the other one (6) comprised partici-
pants aged 45 years. In these studies
(6,9,10), 25(OH)D concentrations were
relatively higher than in our study. A co-
hort study by Forouhi et al. (5) showed
that the baseline concentration of
25(OH)D was inversely associated with
an increased metabolic syndrome risk z
score. However, a study in southern Cal-
ifornia residents (17) did not show a sig-
niﬁcant association between 25(OH)D
and metabolic syndrome, which may be
attributed to extraordinary high levels of
25(OH)D(meanconcentrationwas108.9
nmol/l in men and 101.6 nmol/l in
women).Whetherthereisathresholdora
speciﬁc range for the association between
25(OH)D and metabolic abnormalities
merits further investigation.
Elevated CRP and IL-6 levels have
been found to be positively associated
with metabolic syndrome (8) and in-
versely correlated with 25(OH)D in our
study and other studies (20). Thus, we
furtherexploredwhethertheobservedin-
verse association between 25(OH)D and
metabolic syndrome was mediated by
CRP and/or IL-6. In our study, the asso-
ciation was slightly attenuated but re-
mained signiﬁcant after we control for
CRP and IL-6. Our result was in accor-
dance with the data from the Third Na-
tional Health and Nutrition Examination
Survey (NHANES III) (9) in which
25(OH)D was inversely associated with
metabolic syndrome independent of CRP
levels.
25(OH)D status in our study was
shown to be inversely associated with
A1C and individual metabolic syndrome
features such as fasting glucose, waist cir-
cumference,diastolicbloodpressure,and
triglycerides and positively associated
with HDL cholesterol. However, unlike
some of the previous studies (6,9,10), we
have noticed that plasma 25(OH)D was
associated with triglycerides and HDL
cholesterol only in men but not in
women. These sex-speciﬁc associations
may partly explain the stronger
25(OH)D–metabolic syndrome associa-
tion in men than in women in our study.
Although the mechanistic role of vitamin
D deﬁciency in the pathogenesis of dys-
lipidemia is not well understood, vitamin
Dsupplementationwasreportedtoatten-
uate the beneﬁcial effect of hormone re-
placement therapy on serum lipid levels
(21). Thus, the potential sex-speciﬁc ef-
fects of vitamin D on metabolic disorders
need to be elucidated further.
Insulin resistance is a major underly-
ing mechanism for the metabolic syn-
drome. Experimental studies have
suggested that vitamin D may exert its
beneﬁcial effects by stimulating the ex-
pression of insulin receptor to improve
insulin responsiveness for glucose trans-
port or by controlling calcium inﬂux,
which is essential for the insulin-
mediated intracellular process in insulin-
responsive tissues (7). Most epide-
miologic studies (3,5,19), but not all
(18), suggested that serum 25(OH)D or
the VDR polymorphism was associated
with insulin sensitivity. Moreover, data
from NHANES III documented an ethnic
difference in the association between
25(OH)D and insulin resistance (4), with
a stronger association in Caucasians than
in African Americans, who have much
lower levels of 25(OH)D concentrations.
Interestingly, in our population, with
25(OH)DlevelssimilartothoseofAfrican
Americans, 25(OH)D was also negatively
associated with fasting insulin and
HOMA-IR, and the associations were
stronger among overweight and obese
subjects.
Obesity is known to be associated
with decreased bioavailability of vitamin
D,whichissequesteredinbodyfat(2).In
fact, Forouhi et al. (5) reported a signiﬁ-
cant interaction between 25(OH)D and
BMI on the risk for a 10-year increase in
HOMA-IR. In addition, the release of free
fatty acids from adipose tissue can induce
insulin resistance, whereas 1,25-
dihydroxyvitamin D has been shown to
counteract the free fatty acid–induced in-
sulin resistance (22). The stronger associ-
ation of vitamin D with insulin resistance
among the overweight and obese partici-
pants suggests that adequate vitamin D
status is more important for the preven-
tion of insulin resistance and metabolic
syndrome in these individuals.
OurdatasuggestedthatvitaminDde-
ﬁciencywascommoninmiddle-agedand
elderly Chinese individuals [i.e., 69.2%
participants with 25(OH)D 50 nmol/l].
Indeed, poor vitamin D status in middle
and older Chinese individuals was also
reported previously in two small bone-
related studies conducted in Beijing (23)
and Shenyang (24), respectively. Al-
though little is known regarding to what
extent the high prevalence of vitamin D
deﬁciency in our population could be ex-
plained by certain environmental and/or
genetic factors, plausible explanations in-
clude 1) the skin of elderly individuals is
less efﬁcient for forming vitamin D3, the
major precursor of 25(OH)D (25), 2) use
of vitamin D supplements is rare among
older Chinese individuals (24), 3) unlike
in the United States and other western
countries, few vitamin D–fortiﬁed foods
are available in China, and 4) our study
participants were from a relatively high
latitude, especially those in Beijing (lati-
tude40°north),whohadlower25(OH)D
levels than their Shanghai counterparts
(median 35.6 nmol/l in Beijing vs. 47.6
nmol/l in Shanghai). Hence, attention
should be paid to improving vitamin D
nutritional status in the Chinese popula-
tion, particularly for those who are older,
female, obese, less physically active, and
living in high latitudes and urban areas.
To our knowledge, this is the ﬁrst
study to investigate the distribution and
association of 25(OH)D levels with meta-
bolic syndrome in Chinese individuals.
Themajorstrengthofthisstudyisthatwe
used the data from a large representative
sampleofmiddle-agedandoldermenand
women living in the two largest munici-
palities in China. Our analyses took into
account many potential covariates that
might confound the observed associa-
tions. Furthermore, we completed the
ﬁeld study within a relatively short pe-
riod, which minimized the seasonal vari-
ation in the biomarkers. Nevertheless,
several limitations should be acknowl-
edged. A cause-effect relationship be-
tween25(OH)Dandmetabolicsyndrome
cannot be inferred because of the cross-
sectional nature of the study design. Al-
though data on sun exposure and vitamin
Dsupplementationwerenotavailable,we
used a direct measure of vitamin D status,
which reﬂects cumulative sun exposure
and dietary vitamin D intake. In addition,
because we did not measure serum cal-
ciumandparathyroidhormone,wecould
not determine whether the association of
25(OH)D with metabolic syndrome was
partly mediated by calcium or secondary
hyperparathyroidism. However, data
from NHANES 2003–2004 (10) and the
MedicalResearchCouncilElyProspective
Study (5) suggested that the associations
25(OH)D and metabolic syndrome
1282 DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009between 25(OH)D and insulin resistance
and metabolic syndrome were indepen-
dent of calcium and parathyroid
hormone.
In summary, our ﬁndings suggested
that reduced 25(OH)D is associated with
anincreasedriskofhavingmetabolicsyn-
drome and adverse values for metabolic
syndrome components. The association
of 25(OH)D with insulin resistance is
strongerinoverweightandobeseindivid-
uals than in normal-weight individuals.
Because there is evidence of ethnic varia-
tions in the 25(OH)D effect and limited
data on the association of 25(OH)D with
metabolic syndrome in Asians, our data
provide novel insights into the nature of
this association among Asians. Moreover,
because of the high prevalence of meta-
bolic syndrome and vitamin D deﬁciency
in the middle-aged and elderly Chinese
population, our results may have impor-
tant public health implications. Increased
sun exposure and use of vitamin D sup-
plementsorfortiﬁedfoodsaresimpleand
inexpensive means to prevent vitamin D
deﬁciency and related health problems.
Nevertheless,thebeneﬁtsofvitaminDon
metabolic syndrome and related diseases
such as type 2 diabetes need to be con-
ﬁrmed in future prospective studies and
clinical trials.
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